Illumina Inc (ILMN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Illumina Inc stock (ILMN) is currently trading at $126.20. Illumina Inc PE ratio is 23.16. Illumina Inc PS ratio (Price-to-Sales) is 4.44. Analyst consensus price target for ILMN is $136.05. WallStSmart rates ILMN as Hold.
- ILMN PE ratio analysis and historical PE chart
- ILMN PS ratio (Price-to-Sales) history and trend
- ILMN intrinsic value — DCF, Graham Number, EPV models
- ILMN stock price prediction 2025 2026 2027 2028 2029 2030
- ILMN fair value vs current price
- ILMN insider transactions and insider buying
- Is ILMN undervalued or overvalued?
- Illumina Inc financial analysis — revenue, earnings, cash flow
- ILMN Piotroski F-Score and Altman Z-Score
- ILMN analyst price target and Smart Rating
Illumina Inc
📊 No data available
Try selecting a different time range
ILMN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Illumina Inc (ILMN)
ILMN trades at a significant discount to its Graham intrinsic value of $255.06, offering a 54% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Illumina Inc (ILMN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, eps growth. Concerns around price/book. Fundamentals are solid but monitor weak areas for improvement.
Illumina Inc (ILMN) Key Strengths (5)
Every $100 of shareholder equity generates $33 in profit
Earnings per share surging 86.40% year-over-year
105.91% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong profitability: $20 kept per $100 revenue
Illumina Inc (ILMN) Areas to Watch (5)
Very expensive at 7.0x book value
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 4.4x annual revenue
Modest revenue growth at 5.00%
Decent operational efficiency, solid but not exceptional
Illumina Inc (ILMN) Detailed Analysis Report
Overall Assessment
This company scores 64/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, EPS Growth, Institutional Own.. Profitability is solid with Return on Equity at 33.40%, Profit Margin at 19.60%. Growth metrics are encouraging with EPS Growth at 86.40%.
The Bear Case
The primary concerns are Price/Book, PEG Ratio, Price/Sales. Some valuation metrics including PEG Ratio (2.27), Price/Sales (4.44), Price/Book (6.98) suggest expensive pricing. Growth concerns include Revenue Growth at 5.00%, which may limit upside. Profitability pressure is visible in Operating Margin at 19.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 33.40% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 5.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, EPS Growth) and negatives (Price/Book, PEG Ratio). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ILMN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ILMN's Price-to-Sales ratio of 4.44x trades at a deep discount to its historical average of 12.26x (4th percentile). The current valuation is 86% below its historical high of 32.58x set in Jul 2006, and 28% above its historical low of 3.48x in Nov 2011.
Compare ILMN with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Illumina Inc (ILMN) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Illumina Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 4.3B with 500% growth year-over-year. Profit margins of 19.6% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 500% YoY, reaching 4.3B. This pace significantly outperforms most DIAGNOSTICS & RESEARCH peers.
ROE of 3340.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Illumina Inc maintain 500%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.50, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Illumina Inc.
Bottom Line
Illumina Inc offers an attractive blend of growth (500% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Illumina Inc(ILMN)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.